Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

347 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CREST-UK: Real-world effectiveness, safety and outpatient delivery of CPX-351 for first-line treatment of newly diagnosed therapy-related AML and AML with myelodysplasia-related changes in the UK.
Mehta P, Campbell V, Maddox J, Floisand Y, Kalakonda AJM, O'Nions J, Coats T, Nagumantry S, Hodgson K, Whitmill R, Amott I, Flynn G, Taussig D, Zhao R, Cunningham N, Roset M, Cuadras D, Medalla G, Kuter H, Park S, Legg A, Khan AB. Mehta P, et al. Among authors: campbell v. Br J Haematol. 2024 Oct;205(4):1326-1336. doi: 10.1111/bjh.19622. Epub 2024 Jul 8. Br J Haematol. 2024. PMID: 38977430 Clinical Trial.
Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy.
Othman J, Hwang A, Brodermann M, Abdallah I, McCloskey K, Gallipoli P, Clarke G, Dang R, Vidler J, Krishnamurthy P, Basheer F, Latif AL, Palanicawandar R, Taylor T, Khan A, Campbell V, Hogan F, Kanellopoulos A, Fleming K, Collins A, Dalley C, Loke J, Marshall S, Taussig D, Munisamy S, Loizou E, Yassin H, Dennis M, Zhao R, Belsham E, Murray D, Fowler N, O'Nions J, Khan A, Sellar R, Dillon R. Othman J, et al. Among authors: campbell v. Blood Adv. 2024 Nov 12;8(21):5590-5597. doi: 10.1182/bloodadvances.2024014017. Blood Adv. 2024. PMID: 39265176 Free PMC article.
Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies.
Nicosia L, Spencer GJ, Brooks N, Amaral FMR, Basma NJ, Chadwick JA, Revell B, Wingelhofer B, Maiques-Diaz A, Sinclair O, Camera F, Ciceri F, Wiseman DH, Pegg N, West W, Knurowski T, Frese K, Clegg K, Campbell VL, Cavet J, Copland M, Searle E, Somervaille TCP. Nicosia L, et al. Cancer Cell. 2023 Dec 11;41(12):2136-2153.e13. doi: 10.1016/j.ccell.2023.11.001. Epub 2023 Nov 22. Cancer Cell. 2023. PMID: 37995682 Free article.
Project Lifeline-II: Feasibility of Implementing Screening, Brief Intervention, and Referral to Treatment (SBIRT) in Allegheny County, Pennsylvania.
Cloutier RM, Dowd WN, Aldridge A, Walsh CA, Messman BA, Northcott JL, Talbert A, Manolis C, Campbell V, Pringle JL. Cloutier RM, et al. Among authors: campbell v. Public Health Rep. 2024 Sep 28:333549241277416. doi: 10.1177/00333549241277416. Online ahead of print. Public Health Rep. 2024. PMID: 39342449 Free PMC article.
Intensive care unit admission criteria: a scoping review.
Soares J, Leung C, Campbell V, Van Der Vegt A, Malycha J, Andersen C. Soares J, et al. Among authors: campbell v. J Intensive Care Soc. 2024 Apr 15;25(3):296-307. doi: 10.1177/17511437241246901. eCollection 2024 Aug. J Intensive Care Soc. 2024. PMID: 39224425 Free PMC article.
347 results